Invention Application
- Patent Title: DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
-
Application No.: US17517236Application Date: 2021-11-02
-
Publication No.: US20220162329A1Publication Date: 2022-05-26
- Inventor: Chi-Chung LI , Carol Elaine O'HEAR , Brendan Christian BENDER
- Applicant: Genentech, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Genentech, Inc.
- Current Assignee: Genentech, Inc.
- Current Assignee Address: US CA South San Francisco
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K31/573 ; A61P35/00
Abstract:
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
Information query
